Greater Glasgow and Clyde Medicines

Restrictions:

Restricted to specialist use in accordance with regional protocol in adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

Prescribing Notes:

• The regional protocol for treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib can be found here (NHS network access required).
• Use as monotherapy for the first-line treatment of adults with ALK-positive advanced NSCLC is not recommended by SMC.

BNF Link